What is the current stock price of Aspira Women's Health Inc. (AWH)?

As of the latest market data, Aspira Women's Health Inc. (AWH) is trading at $0.08. The stock has seen a loss of -15.90% today.

Does Aspira Women's Health Inc. (AWH) pay a dividend?

Based on current data, Aspira Women's Health Inc. does not have a confirmed active dividend policy.

What is the market cap of Aspira Women's Health Inc.?

The current market capitalization of Aspira Women's Health Inc. (AWH) is approximately unavailable.

AWH

Aspira Women's Health Inc.·Healthcare

0.08

15.897%(−0.02)

Market Closed

0.04

49.606%(−0.04)

After Hours

Last Updated: — ET

52W L: $0.0852W H: $3.63

AWH NEWS

prnewswire.com

Mar 12

AWH Announces Fourth Quarter and Full Year 2025 Results

Delivered Q4 2025 and FY 2025 revenue of $120.5 million and $500.6 million Expanded Adjusted EBITDA Margin 1 to 25.1% in Q4 2025 and 23.4% for FY 2025 Maintained strong liquidity with $ 85.7 million in cash and no significant near-term debt Retail footprint reaches 48 locations as densification continues NEW YORK, March 12, 2026 /PRNewswire/ - Ascend Wellness Holdings, Inc. ("AWH," "Ascend," or the "Company") (CSE: AAWH-U.CN) (OTCQX: AAWH), a multi-state, vertically integrated cannabis operator, today reported its financial results for the quarter and year ended December 31, 2025. Financial results are reported in accordance with U.S. generally accepted accounting principles ("GAAP"), and all currency is in U.S. dollars.

prnewswire.com

Feb 9

AWH Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Results and Conference Call Date

Q4 2025 and FY 2025 revenue expected to be ~$120 million and ~$500 million, respectively Q4 2025 and FY 2025 Adjusted EBITDA projected at ~$30 million and ~$117 million Balance sheet strength with $86 million cash and no significant debt maturities until 2029 Q4 & FY 2025 earnings call scheduled for Thursday, March 12, at 5:00 PM ET NEW YORK, Feb. 9, 2026 /PRNewswire/ - Ascend Wellness Holdings, Inc. ("AWH", "Ascend" or the "Company") (CSE: AAWH-U) (OTCQX: AAWH), a multi-state, vertically integrated cannabis operator, today announced preliminary, unaudited results for the fourth quarter and year ended December 31, 2025. For the fourth quarter of 2025 ("Q4 2025"), the Company expects net revenue to be approximately $120 million and Adjusted EBITDA to be approximately $30 million, representing an Adjusted EBITDA margin of ~25%.

Company Profile

Aspira Women's Health Inc., together with its subsidiaries, engages in developing and commercializing diagnostic tests for gynecologic disease in the United States. The company provides OVA1, OVERA, and OVA1plus to detect risk of ovarian malignancy in women with adnexal masses. It also offers ASPiRA GenetiX, a genetic test for the risk of gynecologic cancer. In addition, the company operates Aspira Synergy, a testing platform and cloud service for decentralized access of protein biomarker and hereditary genetic testing; and owns and operates ASPiRA LABS, a lab that specializes in applying biomarker-based technologies to address critical needs in the management of gynecologic cancers and disease. Further, its pipeline products include OVAWatch, EndoCheck, and OVAInherit. The company serves physicians, physician office laboratories, and national and regional laboratories. It has a collaborative research agreement with Baylor Genetics; an agreement with Harvard Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Medical University Lodz to evaluate the microRNA technology in combination with Aspira technologies for the development of an early detection test for ovarian cancer; and a strategic alliance with Quest Diagnostics, Incorporated. The company was formerly known as Vermillion, Inc. and changed its name to Aspira Women's Health Inc. in June 2020. Aspira Women's Health Inc. was incorporated in 1993 and is headquartered in Austin, Texas.

Sector

Healthcare

Industry

Medical - Diagnostics & Research

Employees

IPO Date

2000-10-02

Beta

2.01

Websiteaspirawh.com↗